TY - JOUR
T1 - An experimental platform for characterizing cancer biomarkers with capabilities in noninvasive and continuous screening
AU - Honikel, Mackenzie M.
AU - La Belle, Jeffrey T.
N1 - Publisher Copyright:
© 2019 by Begell House,.
PY - 2019
Y1 - 2019
N2 - Early detection is crucial to the proper and effective treatment of two metastatic cancers, prostate cancer and small cell lung cancer. Currently, preventative screenings for these conditions are restricted to high-risk populations and extremely expensive. The discovery of clinically indicative biomarkers has been revolutionary in advancing screening and diagnostic capabilities. Prostate-specific antigen (PSA), an extracellular secreted protein of the prostate gland, and neuron-specific enolase (NSE), an enzyme of neuronal origin, have reported reputable specificity for prostate cancer and small cell lung cancer (SCLC). Current efforts are underway to develop a rapid, label-free means of measuring both PSA and NSE levels in a clinical environment for early screening applications of highly metastatic cancers. Electrochemical impedance spectroscopy (EIS) and impedance time (Z-t) are rapid, sensitive electrochemical techniques previously validated in the detection of several clinically relevant biomarkers, including cardiovascular disease and diabetes mellitus. Herein, we determine the optimal frequencies of PSA (81.38 Hz) and NSE (14.36 Hz) using EIS that are robust across analytical platforms and in the presence of potentially interfering species. The reported empirical evidence supports the prevalence of electrostatic interactions in electrochemical systems and provides alternative theoretical support of previous findings. Finally, Z-t was implemented for its utility in continuous monitoring applications and to lay the foundation for future improvements to continuous sensor platforms.
AB - Early detection is crucial to the proper and effective treatment of two metastatic cancers, prostate cancer and small cell lung cancer. Currently, preventative screenings for these conditions are restricted to high-risk populations and extremely expensive. The discovery of clinically indicative biomarkers has been revolutionary in advancing screening and diagnostic capabilities. Prostate-specific antigen (PSA), an extracellular secreted protein of the prostate gland, and neuron-specific enolase (NSE), an enzyme of neuronal origin, have reported reputable specificity for prostate cancer and small cell lung cancer (SCLC). Current efforts are underway to develop a rapid, label-free means of measuring both PSA and NSE levels in a clinical environment for early screening applications of highly metastatic cancers. Electrochemical impedance spectroscopy (EIS) and impedance time (Z-t) are rapid, sensitive electrochemical techniques previously validated in the detection of several clinically relevant biomarkers, including cardiovascular disease and diabetes mellitus. Herein, we determine the optimal frequencies of PSA (81.38 Hz) and NSE (14.36 Hz) using EIS that are robust across analytical platforms and in the presence of potentially interfering species. The reported empirical evidence supports the prevalence of electrostatic interactions in electrochemical systems and provides alternative theoretical support of previous findings. Finally, Z-t was implemented for its utility in continuous monitoring applications and to lay the foundation for future improvements to continuous sensor platforms.
KW - Cancer biomarker
KW - Continuous monitoring
KW - Electrochemical impedance spectroscopy
KW - Impedance time
KW - Neuron-specific enolase
KW - Optimal frequency
KW - Point-of-care screening
KW - Prostate cancer
KW - Prostate-specific antigen
KW - Small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85067935981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067935981&partnerID=8YFLogxK
U2 - 10.1615/CritRevBiomedEng.2019026426
DO - 10.1615/CritRevBiomedEng.2019026426
M3 - Article
AN - SCOPUS:85067935981
SN - 0278-940X
VL - 47
SP - 217
EP - 234
JO - Critical Reviews in Biomedical Engineering
JF - Critical Reviews in Biomedical Engineering
IS - 3
ER -